Surmodics has announced the commercial release of the Pounce XL thrombectomy system for endovascular removal of acute or chronic clot from peripheral arteries.
Intended for removal of thrombi and emboli from peripheral arteries ranging from 5.5–10mm in diameter, sizes typical of iliac and femoral arteries, the Pounce XL thrombectomy system accompanies the Pounce and Pounce low-profile thrombectomy systems.
The Pounce XL thrombectomy system has been in limited market release (LMR) since January 2025. Anna Marjan, MD, a vascular surgeon at Allina Health Mercy Hospital in Coon Rapids, Minnesota, was among the physicians who used the Pounce XL thrombectomy system during the product’s LMR, a Surmodics press release states.
“Removing organized clot from large peripheral arteries without a surgical cutdown can be very challenging,” she said. “In our first use of the Pounce XL thrombectomy system we were able to extract a large amount of acute and subacute clot from the infrarenal aorta and common iliac arteries in a severely ischemic patient with just three passes of the device.”
An interim analysis of the PROWL registry showed that in 74 patients with acute, subacute, and chronic native infrainguinal vessel limb ischemia, average Pounce thrombectomy platform use time was 20.3 minutes, with 79.7% of patients receiving no additional clot removal treatment of the target lesion after the platform’s use. Device-related adverse events were limited to one report of flow-limiting dissection.
